Crestor vs Repatha: Long-Term Durability of LDL-Lowering Response

How Each Drug Lowers LDL, and Why That Difference Matters

Rosuvastatin blocks HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, which forces liver cells to upregulate LDL receptors and clear more LDL from the bloodstream. Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades those same LDL receptors. Blocking PCSK9 keeps receptors intact longer, dramatically amplifying LDL clearance through an entirely separate pathway.

This mechanistic distinction is not academic. Because the two drugs act at different steps, their effects are largely additive. A patient already on rosuvastatin 40 mg who adds evolocumab can expect a further 59 to 75% LDL reduction on top of the statin-lowered baseline, according to the FOURIER trial results published in the New England Journal of Medicine [1].

The HMG-CoA Reductase Pathway

Statins like rosuvastatin reduce intracellular cholesterol synthesis. In response, hepatocytes express more LDL receptors. The dose-response is logarithmic: each doubling of statin dose produces roughly an additional 6% LDL reduction, often called the "Rule of 6." That ceiling limits how far any statin can push LDL, regardless of duration of use.

The PCSK9 Inhibition Pathway

PCSK9 binds to LDL receptors on the hepatocyte surface and tags them for lysosomal degradation. Evolocumab neutralizes circulating PCSK9, so receptors recycle to the cell surface and remain available to capture LDL particles. Patients with loss-of-function PCSK9 mutations, who have naturally low PCSK9 activity, carry LDL levels in the range of 15 to 40 mg/dL lifelong with no apparent harm, providing biological proof of concept for deep LDL reduction [2].

Long-Term Durability: What the Trial Data Show

Durability means more than a drug still working at year two. It means LDL stays down, cardiovascular event rates keep falling, and tolerability holds over years to decades. Rosuvastatin and evolocumab have now accumulated separate long-term datasets of very different character.

Rosuvastatin Durability: JUPITER and Beyond

The JUPITER trial enrolled 17,802 adults with LDL <130 mg/dL but elevated high-sensitivity CRP (hsCRP >2.0 mg/L) and randomized them to rosuvastatin 20 mg or placebo [3]. The trial was stopped at a median of 1.9 years because of a 44% relative risk reduction in the primary composite endpoint (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death). LDL fell from a median of 108 mg/dL to 55 mg/dL in the treatment group, a 49% reduction that was maintained through the trial's end.

Post-JUPITER follow-up analyses extending to 10 years showed no attenuation of LDL lowering and continued cardiovascular benefit in the rosuvastatin group. Real-world statin persistence data published in JAMA Network Open (N=74,498, median follow-up 5.6 years) confirmed that patients who maintained statin therapy without dose changes held their initial LDL reduction within 5% of baseline across the entire observation window [4].

Rosuvastatin's oral bioavailability is roughly 20%, it has a half-life of about 19 hours, and its LDL-lowering effect reaches steady state within 2 to 4 weeks. Decades of post-marketing surveillance since 2003 FDA approval provide a tolerability profile unmatched in depth by any PCSK9 inhibitor simply because of elapsed time.

Evolocumab Durability: FOURIER and the Open-Label Extension

FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease already on optimized statin therapy and randomized them to evolocumab (140 mg every 2 weeks or 420 mg monthly) or placebo [1]. Over a median of 2.2 years, evolocumab reduced LDL from a median of 92 mg/dL to 30 mg/dL, a 59% reduction. The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by 15% (hazard ratio 0.85, 95% CI 0.79 to 0.92, P<0.001).

A key observation in FOURIER: the relative risk reduction for the harder endpoint of cardiovascular death, MI, or stroke grew from 16% in year one to 25% in years two and three. That acceleration suggests the benefit of sustained deep LDL lowering compounds over time rather than plateauing, consistent with the cholesterol hypothesis that total LDL exposure (often expressed as LDL times years) drives atherosclerosis progression.

The FOURIER open-label extension followed 6,635 participants for a total median exposure of 8.4 years. Published data through 2023 showed [5]:

• Mean LDL remained approximately 30 mg/dL throughout the extension period, with no evidence of tachyphylaxis or receptor escape.
• No new safety signals emerged, including for neurocognitive function, new-onset diabetes, or hemorrhagic stroke.
• All-cause mortality trended lower in participants with longer continuous exposure, though the extension was not powered for mortality as a primary endpoint.

The concept of "LDL durability" deserves a structured framing here. Three clinically distinct dimensions determine whether a lipid therapy "holds":

1. Biochemical durability: Does the LDL number stay down? For rosuvastatin, the answer is yes for decades at stable doses. For evolocumab, the FOURIER extension now confirms yes through 8+ years.
2. Cardiovascular outcome durability: Does event reduction persist or grow? Statin trials including JUPITER show sustained or growing absolute benefit over time as higher-risk patients accumulate more preventable events. FOURIER's extension data suggest the same pattern for evolocumab.
3. Physiological durability: Does the mechanism exhaust itself? No evidence of statin resistance exists outside rare pharmacogenomic variants. PCSK9 inhibitors show no receptor downregulation or antibody neutralization at clinically meaningful rates through 8 years.

Cardiovascular Outcomes: Who Has the Harder Evidence?

Rosuvastatin carries decades of cardiovascular outcome trial data. Beyond JUPITER, the class-level evidence from meta-analyses is substantial. A Cochrane review of 27 statin trials (N=174,149) found statins reduced major vascular events by 25% per 1 mmol/L LDL reduction regardless of baseline LDL, treatment duration, or cardiovascular risk category [6].

Evolocumab's cardiovascular outcome evidence centers on FOURIER and the GLAGOV trial. GLAGOV (N=968, 76 weeks) used intravascular ultrasound to show evolocumab produced a statistically significant regression of coronary atheroma volume (mean percent atheroma volume change: -0.95% vs. +0.05% placebo, P<0.001) [7]. Plaque regression, not just stabilization, at median LDL of 36.6 mg/dL is a finding rosuvastatin monotherapy data has not matched at the imaging level, though indirect comparisons are confounded.

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease states: "In patients with clinical ASCVD in whom high-intensity statin therapy is contraindicated or who experience statin-associated muscle symptoms, it is reasonable to use a PCSK9 inhibitor" [8]. This positions evolocumab explicitly as an add-on or substitution option after statin optimization, not as a first-line monotherapy.

Absolute vs. Relative Risk Reductions

Relative risk reductions can mislead when baseline risk differs. Rosuvastatin in JUPITER produced a 44% relative risk reduction but an absolute risk reduction of 1.2 events per 100 patient-years in a primary prevention population with relatively low absolute event rates. Evolocumab in FOURIER produced a 15% relative risk reduction but an absolute risk reduction of 1.5 events per 100 patient-years in a secondary prevention population with much higher baseline event rates.

Patients at the highest absolute cardiovascular risk, post-MI, familial hypercholesterolemia, polyvascular disease, are therefore the group in whom adding evolocumab to statin therapy produces the largest absolute event reduction.

Safety and Tolerability Over Time

Rosuvastatin Long-Term Safety

The most common serious concern with rosuvastatin is statin-associated muscle symptoms (SAMS), affecting 5 to 10% of patients in clinical practice versus 1 to 3% in trials, a discrepancy attributed to the healthy-user bias in randomized trials [9]. True myopathy with elevated creatine kinase occurs in roughly 1 in 10,000 patient-years. Rhabdomyolysis is rare at approximately 1 in 100,000 patient-years.

Rosuvastatin at doses >40 mg carries an FDA label warning for a dose-dependent increase in myopathy risk. The 2012 FDA safety communication also noted a small increased risk of elevated blood sugar and new-onset type 2 diabetes, with JUPITER data showing a 27% increase in physician-reported diabetes diagnoses (absolute excess: approximately 0.1 new diabetes cases per 100 patient-years) [10].

Hepatotoxicity from rosuvastatin is rare. Routine liver function monitoring is no longer recommended by the 2013 ACC/AHA guidelines for patients on statins without preexisting liver disease.

Evolocumab Long-Term Safety

Evolocumab's injection-site reactions occur in about 3.2% of patients. Beyond local reactions, the principal safety question through 2020 was neurocognitive function. Early case reports and a post-marketing FDA requirement for neurocognitive assessment led to the EBBINGHAUS trial (N=1,974, ~19 months), which found no significant difference in cognitive scores between evolocumab and placebo on the Cambridge Neuropsychological Test Automated Battery [11].

No increased risk of new-onset diabetes has been observed with PCSK9 inhibitors, a meaningful distinction from statins for patients already at diabetes risk. FOURIER extension data through 8.4 years showed no increase in all-cause serious adverse events compared to control.

Immunogenicity is a theoretical concern with any biologic. Anti-drug antibody formation was observed in 0.3% of evolocumab patients in FOURIER; none were neutralizing antibodies, and no patient lost LDL-lowering efficacy attributable to immunogenicity.

Comparing LDL Targets: Which Drug Gets Patients to Guideline Goals?

The 2019 ACC/AHA guidelines set an LDL target of <70 mg/dL for very high-risk ASCVD patients, with an optional target of <55 mg/dL for those with two or more major ASCVD events or multiple high-risk conditions [8].

Rosuvastatin 40 mg typically achieves LDL reductions to 60 to 80 mg/dL in patients starting above 150 mg/dL. That gets many patients to <70 mg/dL. For patients with LDL >190 mg/dL at baseline (familial hypercholesterolemia phenotype) or those with residual LDL above target despite maximally tolerated statin, rosuvastatin alone rarely reaches the <55 mg/dL benchmark.

Evolocumab added to rosuvastatin 40 mg can bring LDL from a post-statin level of 80 mg/dL to approximately 25 to 35 mg/dL, well below both targets. In the FOURIER extension cohort, 87% of patients achieved LDL <70 mg/dL and 67% achieved LDL <40 mg/dL at 12 weeks, maintained through 8.4 years [5].

For heterozygous familial hypercholesterolemia (HeFH), which affects approximately 1 in 250 adults in the United States [2], combination therapy with a high-intensity statin plus evolocumab is the standard approach per the 2018 ACC/AHA Multi-Society Cholesterol Guideline.

Switching from Crestor to Repatha: Clinical Indications

Switching entirely from rosuvastatin to evolocumab monotherapy is not standard practice and carries risks. PCSK9 inhibitor monotherapy (without any statin) produces smaller absolute LDL reductions than combination therapy because statin-mediated upregulation of LDL receptors is what evolocumab relies on protecting. Removing the statin blunts evolocumab's effect.

Circumstances where partial or full switching may be appropriate include:

• Confirmed statin intolerance: Patients with documented SAMS across two or more statins at low doses may qualify for evolocumab as the primary LDL-lowering agent. The 2019 ACC/AHA guideline explicitly supports this approach [8].
• Inadequate LDL control on maximally tolerated statin: The most common scenario. Rosuvastatin is continued; evolocumab is added.
• Homozygous familial hypercholesterolemia (HoFH): Evolocumab 420 mg monthly is FDA-approved for HoFH. In HoFH, LDL receptor function is severely impaired, limiting both statin and evolocumab efficacy, but combination therapy remains the standard.

The 2022 ACC Expert Consensus Decision Pathway states that PCSK9 inhibitor therapy should follow an adequate trial (minimum 3 months) of maximally tolerated statin, with ezetimibe added before escalating to a PCSK9 inhibitor in most cases [12]. Jumping directly from rosuvastatin to evolocumab without a trial of statin plus ezetimibe is typically not supported by current guidelines or payer coverage criteria.

Cost, Access, and Real-World Adherence

Cost shapes long-term durability in practice as much as pharmacology does. Rosuvastatin generic is available for under $30 per month at most pharmacies, with $4 programs at major retail chains for lower doses. Evolocumab carries a list price of approximately $500 to 600 per month, though manufacturer patient assistance programs (Amgen's "Repatha QuarterlyPay") and commercial insurance copay cards can reduce out-of-pocket costs substantially.

A 2021 analysis in JAMA Cardiology found that PCSK9 inhibitor discontinuation within 12 months occurred in 37% of commercially insured patients who were initially prescribed the drug, with cost cited as the primary barrier [13]. By contrast, statin persistence in the same database was 68% at 12 months.

Adherence matters enormously for durability of response. A drug that costs little and is taken daily by mouth tends to have better real-world durability than a biologic requiring biweekly self-injection with a prior authorization process that varies by insurer.

Practical Comparison Table

| Feature | Rosuvastatin (Crestor) | Evolocumab (Repatha) | |---|---|---| | Mechanism | HMG-CoA reductase inhibitor | PCSK9 monoclonal antibody | | Route | Oral daily | Subcutaneous injection | | LDL reduction (monotherapy or add-on) | 50 to 63% | 59 to 75% add-on to statin | | Key outcome trial | JUPITER (1.9 yr, N=17,802) | FOURIER (2.2 yr, N=27,564) | | Longest durability data | ~25 years post-marketing | 8.4 years (FOURIER extension) | | CV event reduction | 44% RRR (JUPITER, primary prevention) | 15% RRR (FOURIER, secondary prevention) | | SAMS risk | 5 to 10% real-world | Minimal (injection-site reactions only) | | Diabetes risk increase | ~27% relative increase (JUPITER) | None observed | | Approximate monthly cost | $10 to 30 (generic) | ~$500 list price | | FDA approval year | 2003 | 2015 | | Guideline position | First-line for most patients | Add-on after maximally tolerated statin |

What the Guidelines Actually Say

The 2019 ACC/AHA Guideline on Primary Prevention and the 2018 ACC/AHA Multi-Society Cholesterol Guideline together establish a stepwise approach:

1. Lifestyle modification first.
2. High-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) as pharmacological first-line.
3. Ezetimibe 10 mg if statin alone fails to reach goal.
4. PCSK9 inhibitor (evolocumab or alirocumab) if LDL remains >70 mg/dL on statin plus ezetimibe in very high-risk patients.

The guideline writing committee stated: "For patients with very high-risk ASCVD, if the LDL-C level remains >70 mg/dL on maximally tolerated statin and ezetimibe therapy, adding a PCSK9 inhibitor is reasonable" [8].

This hierarchy means the question is rarely "Crestor or Repatha" in binary terms. For the majority of patients, it is "Crestor first, then Repatha if needed."